Breaking News Instant updates and real-time market news.

SGYP

Synergy Pharmaceuticals

08:06
10/17/16
10/17
08:06
10/17/16
08:06

Synergy: Plecanatide associated with low adverse events in long-term study

Synergy Pharmaceuticals presented new long-term safety data of plecanatide, its investigational, orally-administered compound currently being evaluated by the U.S. FDA for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. These data, which were presented at the American College of Gastroenterology annual scientific meeting, showed that plecanatide was associated with low adverse events and low discontinuation rates in patients with CIC who received plecanatide once-daily for up to 72 weeks. In this long-term study, which evaluated 2,370 patients, the most common adverse events in both dose groups were diarrhea and urinary tract infection. The remainder of adverse events occurred in less than 2% of patients treated with plecanatide. Adverse events leading to discontinuation occurred in 5.3% of patients treated with plecanatide, with discontinuation due to diarrhea occurring in 3.1% of patients. In addition, this study asked patients about level of treatment satisfaction and desire to continue treatment. The median score for treatment satisfaction was 4.0 and for continuation of treatment was 4.0. The Prescription Drug User Fee Act target action date for plecanatide in CIC is January 29, 2017. In addition, Synergy has already completed patient recruitment for the two double-blind, placebo-controlled Phase 3 clinical trials with plecanatide in IBS-C and remains on-track to report top-line data from both trials in the fourth quarter of this year. Pending approval in the CIC indication, Synergy plans to file a New Drug Application Supplement with Clinical Data for plecanatide in IBS-C in the first quarter of 2017 and expects a 10-month review period from submission.

  • 29

    Jan

SGYP Synergy Pharmaceuticals

12/18/15
SBSH
12/18/15
DOWNGRADE
Target $7
SBSH
Neutral
Synergy Pharmaceuticals downgraded to Neutral from Buy at Citi
Citi analyst Liav Abraham downgraded Synergy Pharmaceuticals (SGYP) to Neutral saying the commercial potential of plecanatide will be "significantly lower" than that of Linzess. He also views the probability of a takeout of the company as less likely. The analyst cut his price target for the shares to $7 from $12. Abraham calls Synergy and Insmed (INSM) his least favored small-cap Specialty Pharma names for 2016.
12/18/15
12/18/15
DOWNGRADE

On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Aixtron (AIXG) downgraded to Equal Weight from Overweight at Morgan Stanley... ArcelorMittal (MT) downgraded to Sector Perform from Outperform at RBC Capital... Biodel (BIOD) downgraded to Market Perform from Outperform at William Blair... Boeing (BA) downgraded to Market Perform from Outperform at Wells Fargo... Bristow Group (BRS) downgraded to Market Perform from Outperform at William Blair... Charles Schwab (SCHW) downgraded to Neutral from Overweight at Piper Jaffray... Denbury Resources (DNR) downgraded at Stifel... EMC Insurance (EMCI) downgraded to Hold from Buy at Sandler O'Neill... Forum Energy (FET) downgraded to Market Perform from Outperform at William Blair... Fossil (FOSL) downgraded to Sell from Neutral at Goldman... GasLog Partners (GLOP) downgraded to Underweight from Neutral at JPMorgan... Herman Miller (MLHR) downgraded to Market Perform from Outperform at Raymond James... Hub Group (HUBG) downgraded to Neutral from Outperform at Baird... Investors Real Estate (IRET) downgraded to Hold from Buy at Wunderlich... Kindred Healthcare (KND) downgraded to Market Perform from Outperform at Avondale... Knight Transportation (KNX) downgraded to Neutral from Buy at Citi... LaSalle Hotel (LHO) downgraded to Underweight from Equal Weight at Barclays... National Oilwell (NOV) downgraded to Market Perform from Outperform at William Blair... Patriot National (PN) downgraded to Market Perform from Outperform at William Blair... Plains All American (PAA) downgraded to Neutral from Accumulate at Seaport Global... Plains GP Holdings (PAGP) downgraded to Neutral from Accumulate at Seaport Global... RLJ Lodging Trust (RLJ) downgraded to Underweight from Equal Weight at Barclays... Sandvik AB (SDVKY) downgraded to Underperform from Hold at Jefferies... Seadrill Partners (SDLP) downgraded to Neutral from Buy at Seaport Global... Synergy Pharmaceuticals (SGYP) downgraded to Neutral from Buy at Citi... Texas Instruments (TXN) downgraded to Market Perform from Outperform at Bernstein... Tim Participacoes (TSU) downgraded to Sell from Neutral at Goldman... Ultra Petroleum (UPL) downgraded on commmodity outlook, debt at Stifel.
09/14/16
09/14/16
NO CHANGE

Citi calls Synergy Pharmaceuticals a potential target for Takeda
09/14/16
SBSH
09/14/16
NO CHANGE
Target $4
SBSH
Neutral
Citi views Synergy Pharmaceuticals as potential target for Takeda
Citi analyst Liav Abraham calls Synergy Pharmaceuticals (SGYP) the most likely potential target for Takeda Pharmaceutical (TKPYY) among her coverage universe. The Financial Times earlier today reported that Takeda is ready to spend as much as $15B in acquisitions to expand its business in the United States. Abraham has a Neutral rating on Synergy with a $4 price target. The analyst sees Synergy as a potential target given the "extensive resources" needed to commercialize its lead asset, plecanatide, as well as Takdea's presence in the irritable bowel syndrome/chronic idiopathic constipation space. Shares of Synergy are up 6% to $5.18 in early trading.

TODAY'S FREE FLY STORIES

EHC

Encompass Health

$51.31

-0.15 (-0.29%)

06:11
01/17/18
01/17
06:11
01/17/18
06:11
Initiation
Encompass Health initiated  »

Encompass Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$176.19

-0.9 (-0.51%)

06:09
01/17/18
01/17
06:09
01/17/18
06:09
Downgrade
Apple rating change  »

Longbow downgrades Apple…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

SPG

Simon Property

$165.04

-0.47 (-0.28%)

, SBUX

Starbucks

$60.56

0.16 (0.26%)

06:09
01/17/18
01/17
06:09
01/17/18
06:09
Periodicals
Simon, Starbucks reach settlement over Teavana closures, WSJ reports »

Simon Property Group…

SPG

Simon Property

$165.04

-0.47 (-0.28%)

SBUX

Starbucks

$60.56

0.16 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 31

    Jan

GOOG

Alphabet

$1,121.76

-0.5 (-0.04%)

, GOOGL

Alphabet Class A

$1,130.70

0.05 (0.00%)

06:08
01/17/18
01/17
06:08
01/17/18
06:08
Hot Stocks
YouTube implements additional requirements for YouTube Partner Program »

In a blog post, Neal…

GOOG

Alphabet

$1,121.76

-0.5 (-0.04%)

GOOGL

Alphabet Class A

$1,130.70

0.05 (0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 23

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 18

    Mar

TPC

Tutor Perini

$27.00

-0.5 (-1.82%)

06:07
01/17/18
01/17
06:07
01/17/18
06:07
Hot Stocks
Tutor Perini subsidiary awarded three new projects for $67M »

Tutor Perini's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORBK

Orbotech

$51.47

0.38 (0.74%)

06:05
01/17/18
01/17
06:05
01/17/18
06:05
Earnings
Orbotech sees FY18 revenue up 12%-14% »

Sees 12-14% revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORBK

Orbotech

$51.47

0.38 (0.74%)

06:04
01/17/18
01/17
06:04
01/17/18
06:04
Earnings
Breaking Earnings news story on Orbotech »

Orbotech sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$4.11

-0.14 (-3.29%)

06:03
01/17/18
01/17
06:03
01/17/18
06:03
Hot Stocks
Amarin initiates clinical development of Vascepa in China »

Amarin's partner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUVA

NuVasive

$51.99

-1.34 (-2.51%)

06:03
01/17/18
01/17
06:03
01/17/18
06:03
Downgrade
NuVasive rating change  »

Wells Fargo sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.55 (-2.93%)

06:03
01/17/18
01/17
06:03
01/17/18
06:03
Hot Stocks
GE: Peter Stracar to succeed Mark Hutchinson as President and CEO of GE Europe »

GE announces the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

KL

Kirkland Lake Gold

$16.74

0.62 (3.85%)

06:03
01/17/18
01/17
06:03
01/17/18
06:03
Hot Stocks
Kirkland Lake Gold sees FY18 production growth to over 620,000 ounces »

Highlights of 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORBK

Orbotech

$51.47

0.38 (0.74%)

06:02
01/17/18
01/17
06:02
01/17/18
06:02
Earnings
Orbotech reports preliminary Q4 revenue of about $256M, consensus $250.16M »

Gross margin is expected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$24.66

-0.75 (-2.95%)

06:01
01/17/18
01/17
06:01
01/17/18
06:01
Periodicals
Twitter sued by TWiT for breach of contract, infringement, TechCrunch reports »

Twitter is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

SLGN

Silgan Holdings

$29.29

-0.23 (-0.78%)

, CCK

Crown Holdings

$57.79

-0.31 (-0.53%)

05:58
01/17/18
01/17
05:58
01/17/18
05:58
Downgrade
Silgan Holdings, Crown Holdings, Berry Global, Ball Corp. rating change  »

Silgan Holdings…

SLGN

Silgan Holdings

$29.29

-0.23 (-0.78%)

CCK

Crown Holdings

$57.79

-0.31 (-0.53%)

BERY

Berry Global

$59.13

-1.1 (-1.83%)

BLL

Ball Corp.

$38.39

0.49 (1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 07

    Feb

  • 08

    Feb

ABB

ABB

$28.07

-0.02 (-0.07%)

05:55
01/17/18
01/17
05:55
01/17/18
05:55
Downgrade
ABB rating change  »

ABB downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

IFF

International Flavors

$152.54

-1.16 (-0.75%)

05:54
01/17/18
01/17
05:54
01/17/18
05:54
Upgrade
International Flavors rating change  »

International Flavors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADNT

Adient

$81.91

-0.51 (-0.62%)

05:54
01/17/18
01/17
05:54
01/17/18
05:54
Downgrade
Adient rating change  »

Adient downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

AEP

American Electric

$67.50

0.04 (0.06%)

05:53
01/17/18
01/17
05:53
01/17/18
05:53
Upgrade
American Electric rating change  »

American Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPG

PPG

$116.64

-1.53 (-1.29%)

05:53
01/17/18
01/17
05:53
01/17/18
05:53
Downgrade
PPG rating change  »

PPG downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

NBR

Nabors Industries

$8.23

0.04 (0.49%)

05:52
01/17/18
01/17
05:52
01/17/18
05:52
Downgrade
Nabors Industries rating change  »

Nabors Industries resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

ETH

Ethan Allen

$28.15

-0.5 (-1.75%)

05:52
01/17/18
01/17
05:52
01/17/18
05:52
Downgrade
Ethan Allen rating change  »

Ethan Allen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

QTS

QTS Realty Trust

$52.47

0.82 (1.59%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Downgrade
QTS Realty Trust rating change  »

QTS Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LQ

La Quinta

$18.44

-0.03 (-0.16%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Upgrade
La Quinta rating change  »

La Quinta upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASND

Ascendis Pharma

$47.60

1.02 (2.19%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Recommendations
Ascendis Pharma analyst commentary  »

Ascendis Pharma price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLX

Shell Midstream

$30.74

0.21 (0.69%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Downgrade
Shell Midstream rating change  »

Shell Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.